Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2000 Jun;76(896):340–344. doi: 10.1136/pmj.76.896.340

Trends in diagnostic and therapeutic criteria in Graves' disease in the last 10 years

F Escobar-Jimenez 1, M Fernandez-Soto 1, V Luna-Lopez 1, M Quesada-Charneco 1, D Glinoer 1
PMCID: PMC1741609  PMID: 10824047

Abstract

A questionnaire describing a typical clinical case of Graves' disease and 10 variations on it was mailed to 70 Spanish units of endocrinology with the aim of assessing the new diagnostic and therapeutic trends for hyperthyroidism caused by Graves' disease in Spain and to compare the results obtained from previous studies carried out in Europe and Spain 10 years previously.
  Responses indicated that thyrotrophin (98%) and free thyroxine (88%) were the most used tests in the in vitro diagnosis of Graves' disease with a significant decrease in the use of total thyroxine, total triiodothyronine, and thyroglobulin in comparison with the surveys conducted 10 years previously in Europe and Spain. The presence of antibodies against the thyrotrophin receptor was the most frequently used immune marker in the diagnosis (78%) and the new use of antithyroperoxidase antibodies (36%) in diagnosis is noteworthy. Antithyroid drugs remain the treatment of choice (98%). Surgery was used mainly for large size goitres (33%) and radioiodine for recurrences after medical (61%) or surgical (80%) treatment.
  In conclusion, the responses obtained from this questionnaire provide insight into current specialist diagnostic and therapeutic practices with respect to Graves' disease and which could be of value to non-specialist units of endocrinology.


Keywords: Graves' disease; antithyroid drugs; radioiodine; surgery

Full Text

The Full Text of this article is available as a PDF (114.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartalena L., Marcocci C., Bogazzi F., Manetti L., Tanda M. L., Dell'Unto E., Bruno-Bossio G., Nardi M., Bartolomei M. P., Lepri A. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med. 1998 Jan 8;338(2):73–78. doi: 10.1056/NEJM199801083380201. [DOI] [PubMed] [Google Scholar]
  2. Campos Pastor M. M., Fernández Soto M. L., Escobar-Jiménez F., Barredo Acedo F., Ruiz de Almodóvar M. Evolución inmunológica y de la función tiroidea a largo plazo en la enfermedad de Graves según distintas opciones terapéuticas. Med Clin (Barc) 1994 Apr 2;102(12):446–450. [PubMed] [Google Scholar]
  3. Glinoer D., Hesch D., Lagasse R., Laurberg P. The management of hyperthyroidism due to Graves' disease in Europe in 1986. Results of an international survey. Acta Endocrinol Suppl (Copenh) 1987;285:3–23. [PubMed] [Google Scholar]
  4. Hay I. D., Bayer M. F., Kaplan M. M., Klee G. G., Larsen P. R., Spencer C. A. American Thyroid Association assessment of current free thyroid hormone and thyrotropin measurements and guidelines for future clinical assays. The Committee on Nomenclature of the American Thyroid Association. Clin Chem. 1991 Nov;37(11):2002–2008. [PubMed] [Google Scholar]
  5. Leech N. J., Dayan C. M. Controversies in the management of Graves' disease. Clin Endocrinol (Oxf) 1998 Sep;49(3):273–280. doi: 10.1046/j.1365-2265.1998.00558.x. [DOI] [PubMed] [Google Scholar]
  6. Nagayama Y., Izumi M., Nagataki S. The management of hyperthyroidism due to Graves' disease in Japan in 1988. The Japan Thyroid Association. Endocrinol Jpn. 1989 Apr;36(2):299–314. doi: 10.1507/endocrj1954.36.299. [DOI] [PubMed] [Google Scholar]
  7. Nicoloff J. T., Spencer C. A. Clinical review 12: The use and misuse of the sensitive thyrotropin assays. J Clin Endocrinol Metab. 1990 Sep;71(3):553–558. doi: 10.1210/jcem-71-3-553. [DOI] [PubMed] [Google Scholar]
  8. Perrild H., Grüters-Kieslich A., Feldt-Rasmussen U., Grant D., Martino E., Kayser L., Delange F. Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol. 1994 Nov;131(5):467–473. doi: 10.1530/eje.0.1310467. [DOI] [PubMed] [Google Scholar]
  9. Pruyn S. C., Phelan J. P., Buchanan G. C. Long-term propranolol therapy in pregnancy: maternal and fetal outcome. Am J Obstet Gynecol. 1979 Oct 15;135(4):485–489. doi: 10.1016/0002-9378(79)90436-8. [DOI] [PubMed] [Google Scholar]
  10. Schifferdecker E., Kühnl P., Schöffling K., Manfras B., Holzberger G., Spielmann W., Böhm B. O. Immunogenetic markers in patients with Graves' disease. Klin Wochenschr. 1991 Apr 4;69(6):256–260. doi: 10.1007/BF01666851. [DOI] [PubMed] [Google Scholar]
  11. Singer P. A., Cooper D. S., Levy E. G., Ladenson P. W., Braverman L. E., Daniels G., Greenspan F. S., McDougall I. R., Nikolai T. F. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA. 1995 Mar 8;273(10):808–812. [PubMed] [Google Scholar]
  12. Solomon B., Glinoer D., Lagasse R., Wartofsky L. Current trends in the management of Graves' disease. J Clin Endocrinol Metab. 1990 Jun;70(6):1518–1524. doi: 10.1210/jcem-70-6-1518. [DOI] [PubMed] [Google Scholar]
  13. Törring O., Tallstedt L., Wallin G., Lundell G., Ljunggren J. G., Taube A., Säf M., Hamberger B. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab. 1996 Aug;81(8):2986–2993. doi: 10.1210/jcem.81.8.8768863. [DOI] [PubMed] [Google Scholar]
  14. Wartofsky L., Glinoer D., Solomon B., Nagataki S., Lagasse R., Nagayama Y., Izumi M. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid. 1991;1(2):129–135. doi: 10.1089/thy.1991.1.129. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES